Novel research has suggested the gut microbiome is involved in multiple sclerosis and could be a treatment target.
Browsing: Demyelinating disease
Luciano Rossetti discusses the recent European Commission cladribine approval, as well as the current outlook for the multiple sclerosis drug pipeline.
Researchers discover latent human herpes virus 6 may interfere with the brains ability to repair damaged myelin in brain diseases such as multiple sclerosis.
Today marks World MS Day, a day to bring the global MS community together to raise awareness, celebrate pioneering research, and look ahead to the future.
Michael Pender discusses promising interim findings from a Phase 1 study investigating a novel treatment for multiple sclerosis.
Researchers highlight Rab32 as a potential cause and treatment target for multiple sclerosis.
An evaluation of ‘IL4I1 augments CNS remyelination and axonal protection by modulating T-cell driven inflammation’, recently published in Brain.
A small, preliminary study investigating the relationship between multiple sclerosis and the Epstein-Barr virus suggests a potential novel treatment for progressive multiple sclerosis.
Autoantibodies occur in many different nervous system disorders, and are increasingly being found in disorders not traditionally associated with the immune system. Determining if the autoantibodies play a functional or pathogenic role is critical in selecting the most appropriate treatment options.
This article examines a number of different disease-modifying therapy strategies for the treatment of relapsing-remitting multiple sclerosis.